Lead Product(s): Neostigmine Methyl Sulfate
Therapeutic Area: Musculoskeletal Product Name: Bloxiverz
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Exela Pharma Sciences, LLC.
Deal Size: $42.0 million Upfront Cash: $14.5 million
Deal Type: Divestment July 01, 2020
Company announced the sale of its portfolio of sterile injectable drugs used in the hospital setting, including three commercial products, Bloxiverz®, Vazculep®, and Akovaz®, as well as Nouress™ o Exela Sterile Medicines LLC.